FERTILPLUS PARTNERS, LLC
Home Product About Us Publications Glossary Contact Us
     
The Product  
     
Recombinant equine FSH has been shown to induce development of numerous pre-ovulatory follicles in the ovary of the mare. An increase in the number of pre-ovulatory follicles increases the chances of pregnancy or the number of embryos for embryo transfer after the mare is bred. Recombinant equine FSH was developed as a single chain gonadotropin that conveys to the hormone multiple benefits such as increased stability and efficiency as well as ease of production in the laboratory. Briefly, the treatment protocol involves intramuscular (IM) injections 1-2 times per day over a 5-7 day period starting approximately 4 days post-ovulation in cycling mares. A similar protocol is used for anestrous mares without artificial lights starting at any time early February in the non-breeding season. A detailed protocol is included in the package.

Benefits:
  • Enhances the number of pre-ovulatory follicles which results in multiple ovulations in mares for embryo transfer thus assuring at least 2 embryos per recovery.
  • Induces ovulation in the non-breeding season without artificial lights so foals can be born earlier the following year.
  • Mares with conception problems.
  • For advanced reproductive technology techniques such as ovum pickup and intra-cytoplasmic sperm injection (ICIS).
  • Produces follicles in mares that had surgery to remove a granulosa cell tumor.
  • Induces follicular development in mares with seasonal or lactational anestrus.

In summary, Fertilplus recombinant equine FSH will reduce the cost and labor related to breeding mares by increasing the number of embryos to transfer, decreasing conception problems and lengthening the time of the breeding season. It also has the potential for increasing the number of oocytes for ICIS. Research in the area of ICIS is planned for the future.
Copyright c 2018. Fertilplus Partners, LLC. All rights reserved.
Web site designed by Wanda Smith and last modified on: 8/29/2018